Phosphorylated FTY720 Promotes Astrocyte Migration Through Sphingosine-1-phosphate Receptors
Overview
Authors
Affiliations
Sphingosine-1-phosphate (S1P) receptors are widely expressed in the central nervous system where they are thought to regulate glia cell function. The phosphorylated version of fingolimod/FTY720 (FTY720P) is active on a broad spectrum of S1P receptors and the parent compound is currently in phase III clinical trials for the treatment of multiple sclerosis. Here, we aimed to identify which cell type(s) and S1P receptor(s) of the central nervous system are targeted by FTY720P. Using calcium imaging in mixed cultures from embryonic rat cortex we show that astrocytes are the major cell type responsive to FTY720P in this assay. In enriched astrocyte cultures, we detect expression of S1P1 and S1P3 receptors and demonstrate that FTY720P activates Gi protein-mediated signaling cascades. We also show that FTY720P as well as the S1P1-selective agonist SEW2871 stimulate astrocyte migration. The data indicate that FTY720P exerts its effects on astrocytes predominantly via the activation of S1P1 receptors, whereas S1P signals through both S1P1 and S1P3 receptors. We suggest that this distinct pharmacological profile of FTY720P, compared with S1P, could play a role in the therapeutic effects of FTY720 in multiple sclerosis.
Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis.
Theophanous S, Sargiannidou I, Kleopa K Int J Mol Sci. 2024; 25(17).
PMID: 39273535 PMC: 11395575. DOI: 10.3390/ijms25179588.
Jiang H, Zhou C, Qiu L, Gropler R, Brier M, Wu G ACS Chem Neurosci. 2023; 14(22):4039-4050.
PMID: 37882753 PMC: 11037862. DOI: 10.1021/acschemneuro.3c00581.
Roggeri A, Olivero G, Usai C, Vanmierlo T, Pittaluga A Cells. 2023; 12(19).
PMID: 37830557 PMC: 10571862. DOI: 10.3390/cells12192343.
The Effects of Antipsychotics in Experimental Models of Krabbe Disease.
Sharma K, Dev K Biomedicines. 2023; 11(5).
PMID: 37238985 PMC: 10215783. DOI: 10.3390/biomedicines11051313.
Kihara Y, Chun J Pharmacol Ther. 2023; 246:108432.
PMID: 37149155 PMC: 10860660. DOI: 10.1016/j.pharmthera.2023.108432.